Iterum Therapeutics (ITRM) Competitors $0.98 -0.02 (-2.00%) Closing price 04:00 PM EasternExtended Trading$0.98 0.00 (0.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. BIOA, MOLN, ALEC, VTYX, LXEO, THTX, BDTX, ALTS, LYEL, and IKTShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), Lyell Immunopharma (LYEL), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Inhibikase Therapeutics BioAge Labs (NASDAQ:BIOA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Do institutionals and insiders hold more shares of BIOA or ITRM? 9.2% of Iterum Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is BIOA or ITRM more profitable? Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Iterum Therapeutics N/A N/A -71.37% Which has stronger earnings & valuation, BIOA or ITRM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AIterum TherapeuticsN/AN/A-$24.77M-$0.99-0.99 Does the media refer more to BIOA or ITRM? In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 1.89 beat BioAge Labs' score of 0.93 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment BioAge Labs Positive Iterum Therapeutics Very Positive Do analysts recommend BIOA or ITRM? Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 818.37%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryIterum Therapeutics beats BioAge Labs on 6 of the 8 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40M$2.69B$5.53B$9.30BDividend YieldN/A1.70%4.59%4.03%P/E RatioN/A8.9428.5619.60Price / SalesN/A427.61359.9473.66Price / CashN/A22.3424.7327.56Price / Book-6.534.608.155.55Net Income-$24.77M$30.99M$3.24B$257.73M7 Day Performance5.04%0.77%2.03%0.95%1 Month Performance-1.10%23.11%8.29%10.68%1 Year Performance-37.97%-5.46%28.40%15.67% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.0705 of 5 stars$0.98-2.0%$9.00+818.4%-39.0%$40MN/A0.0010Positive NewsGap UpBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/AMOLNMolecular Partners3.0832 of 5 stars$3.61-4.0%$12.00+232.4%-42.6%$151.81M$2.23M-1.88180ALECAlector3.8402 of 5 stars$1.44-4.6%$4.00+177.8%-69.9%$150.99M$100.56M-1.14270VTYXVentyx Biosciences3.4826 of 5 stars$2.04-1.9%$10.00+390.2%+9.8%$148.01MN/A-1.1730Positive NewsLXEOLexeo Therapeutics2.1689 of 5 stars$4.54+2.0%$16.60+265.6%-74.8%$147.73M$650K-1.3858Gap UpHigh Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+119.5%$147.14M$85.87M-39.63140Earnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.8872 of 5 stars$2.50-3.1%$12.80+412.0%-48.0%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.135 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.4878 of 5 stars$9.15-5.6%$15.00+63.9%-71.7%$143.49M$60K-0.37270News CoveragePositive NewsIKTInhibikase Therapeutics1.2114 of 5 stars$1.93+2.1%$6.50+236.8%+33.3%$143.48MN/A-0.726 Related Companies and Tools Related Companies BioAge Labs Alternatives Molecular Partners Alternatives Alector Alternatives Ventyx Biosciences Alternatives Lexeo Therapeutics Alternatives Theratechnologies Alternatives Black Diamond Therapeutics Alternatives ALT5 Sigma Alternatives Lyell Immunopharma Alternatives Inhibikase Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
